New Frontiers for Risk Stratification Assays for Acute Coronary Syndrome - The Gen6 Assay for hs cTnT

Related Links

• Lp(a) Screening at Least Once a Lifetime! Unwrapping the What, Why and How’s of Lipoprotein(a)
• NT-proBNP as a predictor of Cardio-renal Complications in PwD
• Safety of Rx Optimisation Post AHF Hospitalization
• Practical Implementation of GDMT Optimisation – The ATP in NZ
• Use of Rapid Algo for Suspected AMI – Faster Triage of ED Patients
• Navigating Cardiotoxicity – Value of Cardiac Biomarkers
• DROP Asian ACS – Study Results and Practical Approach
• The Importance of Early Diagnosis and Management of AHF
• Integrative Approaches to Managing Diabetes and Cardiovascular Disease
• Optimising GDMT Post AHF Discharge – APAC APSC Consensus Highlights
• Initiation of GDMT Therapy in Patients Discharged Post AHF – What are the Guardrails?
• Enhancing Diabetes and Cardiovascular Management with Continuous Glucose Monitoring
• New Frontiers for Risk Stratification Assays for Acute Coronary Syndrome – The Gen6 Assay for hs cTnT
• NT-proBNP for Rapid Optimisation of GDMT in AHF Patients in Japan
• ACC 2025 Spotlight: DROP-Asian ACS Interim Analysis Highlights Regional Gains in NSTEMI Care
• Empowering the Everyday: AI-enabled CGM Is the Next Leap in Diabetes Care
• Lipoprotein(a) in clinical practice
• Diabetes and Hajj: Doctor’s Awareness Program
• STRONG-HF Japan Study
• Diabetes and Ramadan: Public Awareness Program
• Innovative Strategies to Optimise Heart Failure GDMT at Prince Wales Hospital’s Heart Failure Clinic
• STRONG-HF Recommended in Updated China National Heart Failure Guideline 2023
• Rapid Titration (RaT) Pathway For Optimising Heart Failure GDMT with comprising several hospitals in Northland
• Ramadan & Diabetes
• International Speaker Program (ISP) From Diabetes to Wellbeing: A Global Dialogue on Holistic Health
• Reducing Mortality and Readmission with HF Multidisciplinary Model of Care
• Implementing 0/1-Hour Algorithm using High-Sensitivity Cardiac Troponin in the Emergency Department
• Culturally Sensitive Diabetes Care
• What Causes Falsely High & Low HbA1c Reading?
• Menopause and Diabetes
• World Anaesthesia Day: Dawn of a New Era in the Management of Perioperative Myocardial Infarction (PMI)
• EMPORIUM – Full Throttle Against HF: From Detection to Protection
• Every Heartbeat Counts: Take Action & Make an Impact This World Heart Day
• The effectiveness of telemonitoring and integrated personalised diabetes management in people with insulin-treated type 2 diabetes mellitus
• Screening for Occult Heart Failure (HF) in Type 2 Diabetes Mellitus (T2DM) using NT-proBNP
• Value of biomarker in HFpEF Diagnosis
• Chinese expert consensus on the risk assessment and management of panvascular disease in patients with type 2 diabetes mellitus (2022 edition)
• Communicating the value of CVD screening in T2DM to patients
• Lipoprotein(a): The science behind the Risk Factor
• Sex-specific Differences in Heart Failure
• Management of CVD in Patients with Diabetes
• STRONG-HF: Enhancing GDMT regimen in Asia
• Heart Failure Care Beyond City Limits: Insights from a Cardiologist
• Implementation of STRONG-HF protocol in heart failure management: an Australian perspective
• Unleashing the Power of STRONG-HF: Enabling Transformation in Heart Failure Management Across China
• When every minute counts: A deep dive into IJN Malaysia’s quest for rapid triage for chest pain patients in the ED
• Reshaping HF Management at NHCS
• Screening & Diagnosis of Heart Failure in Pre-Diabetic and Diabetic Patients
• Elevating CVD management in APAC to its Zenith- with Cardiac biomarkers 
• Quantum leap in reducing rehospitalization in HF by 70-80% – How and where?
• 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
• STRONG-HF: Rapid Uptitration of Guideline Directed Medical Therapy for Heart Failure
• Guidelines Interpretation – Guidelines for the management of chronic heart failure in dialysis patients in China
• Heart failure management in Australia and the role of NT-proBNP in monitoring and treatment
• Download APAC STRONG-HF Master Pack: First-hand Insights from Prof Mebazaa on Heart Failure Treatment Monitoring
• Perioperative myocardial injury (PMI) management: Challenges and feasibility of active screening in non-cardiac surgeries
• Heart Failure Management in India – Overcoming Present Challenges
• STRONG-HF Trial highlighting benefits of treatment optimisation
• STRONG-HF: Implementation of GDMT Heart Failure Therapy & Post-discharge Heart Failure Management
• NT-proBNP and ECHO in heart failure – do they always go hand in hand?
• Rapid ACS Rule Out in Emergency Patients
• How to Implement the 0-h/1-h Algorithm to your Institute?
• High Sensitivity Cardiac Troponins and ACS – the Malaysian Experience
• APAC Heart Failure Gap Report
• Rational use of troponin and optimal management of cardiovascular diseases</strong>
• Value of NT-ProBNP for Treatment Monitoring in CHF
• The evidence for 0/1-hour algorithm for Asia? DROP-Asian ACS Study
• Process Optimization for Emergency hs-TnT Detection
• Clinical Application NT-proBNP in CKD (Chronic Kidney Diseases) Patients with Cardiovascular Diseases
• Uncovering the Cardio-renal Risks of Chinese T2DM patients: Back to the Future with CUHK!
• High Sensitivity Troponin vs Conventional Troponin: An Expert View
• The rationale for the use of hs-cTn in the optimal management of ACS
• Management of Diabetes in Japan – Can Patients Play a More Significant Role?
• T2DM Patient Support Program in Hong Kong and the Value of NT-proBNP
• Role of Diagnostics: NT-proBNP in management of Heart Failure
• Taking Diabetes to Heart: Value of Cardiovascular Biomarkers for your Diabetic Patients
• Rapid algorithms for hs-cTn in ED: Boon or Bane?
• 2021 ESC Heart Failure Guidelines: What’s new?
• Heart Failure in Hong Kong- Present Challenges and Future Strategies
• Tips for implementing ESC high sensitivity cardiac troponin (hs-cTn) rapid algorithms for triage of AMI patients
• Rapid Algorithms for Faster Triage of ED Patients with Suspected AMI – What Are We Waiting For?
• Comparing the ESC high sensitivity cardiac troponin (hs-cTn) rapid algorithms for triage of AMI patients
• STROKESTOP II Study: Precision risk screening for atrial fibrillation in elderly
• Atrial Fibrillation in Elderly: Screening tools and role of NT-proBNP
• Advantages of early NT-proBNP testing in patients suspected with heart failure
• NT-proBNP: Increasing Clinical Confidence in Heart Failure Management
• What is the Peptide for Life initiative?
• Digital Prediction Platforms: A catalyst towards personalized CVD prognosis
• Heart Failure in Asia – Present Challenges and Future Strategies
• Perioperative Myocardial Infarction in Non-Cardiac Surgery – Why Measuring Troponin is Important?
• Heart Failure Prevention in T2DM – Essence of JCS/JDS joint consensus
• Clinical Cases: Differentiating acute from chronic cardiac conditions
• Clinical Cases: Diagnostic relevance of elevated hs-cTnT
• Clinical Cases from Korea: Serial NT-proBNP measurement and Heart Failure prognosis
• Clinical Cases from Korea: NT-proBNP for Differential diagnosis of patients with dyspnoea
• Clinical Cases from Korea: Value of NT-proBNP in Cardiomyopathy
• Clinical Cases from Korea: High NT-proBNP levels useful in differential diagnosis of HF
• CVD Management in T2DM – JCS and JDS Joint Consensus
• ESC Recommendation: High sensitivity troponin assay vs conventional assay
• ESC Recommendation: Rapid algorithms using hs troponin in ED
• Dr David Sim’s Clinical Cases: NT-proBNP in Heart Failure Patients
• CANVAS (CANagliflozin cardioVascular Assessment Study): NT-proBNP and CVD risk reduction
• Clinical Cases: Elevations of hs-TnT in Non-cardiac Conditions
• Clinical Cases: hs-TnT in Patients with End Stage Renal Failure
• Clinical Cases: Serial Monitoring Differentiates Acute and Chronic hs-TnT Elevation
• Dr Lee’s Clinical Cases: hs-TnT Chronic Elevation non-AMI cases
• Dr Lee’s Clinical Cases: hs-TnT Early “Rule-In” for AMI
• FAQ: NT-proBNP Interpretation in Multiple Scenarios
• FAQ: NT-proBNP vs Cardiac Medications
• FAQ: Role of NT-proBNP in Heart Failure Management
• At the forefront of Acute Coronary Syndrome management in ED
• What should we take note of when using hs-TnT for CKD patient?
• Clinical Relevance – High-Sensitivity Troponin Results Influenced by Age
• Clinical Relevance of hs-TnT gender specific cut-offs
• Recommended Steps to Implement 0h/1h Algorithm in Asia
• Setting sight on breakthrough diagnostics
• Benefits of 0h/1h Algorithm in a Thai Institution
• Benefits of 0h/1h Algorithm to Patients in Asia
• Recommendations of IFCC on Natriuretic Peptide Testing
• How will NT-proBNP testing evolve in the future?
• Is NT-proBNP validated for different population groups?
• Reference ranges for NT-proBNP & hs-TnT in Asian populations
• How to Implement ESC Rapid Algorithm Successfully?
• The Changes in Rapid Algorithms for Acute Coronary Syndrome
• Sex Differences in Troponin Levels – affecting high-sensitivity cardiac troponin (hs-cTn) levels
• DAPA-HF and EMPEROR-Reduced Study Highlights
• The role of biomarkers in HF
• Digital health in HF management
• Benefits of the 0h/1h algorithm in a Japanese institution
• Serial testing of hs cTn rules out low risk of AMI
• Patient Case Studies Using 0h/1h Algorithm
• Latest IFCC Recommendations for Natriuretic Peptides in Heart Failure – Analytics and Clinical Considerations
• BNP vs NT-proBNP: An Expert View
• Natriuretic Peptide Measurement during ARNi Treatment
• Impact of ARNi Therapy on Natriuretic Peptide Use
• Summary of APSC High Sensitivity Troponin T Consensus
• NT-proBNP in Hospital & Ambulatory Settings: Evidence to Clinical Practice
• How to Use NT-proBNP for Prognosis and Monitoring?
• What Should Hospitals Consider when Implementing Rapid Algorithm?
• Early triage of patients with acute chest pain with hs-TnT 0h/1h Algorithm
• APSC hs-TnT Consensus & Future Use of Biomarker in T2DM & COVID-19
• TRAPID-AMI sub-study: Use of very low concentration of hs-TnT to rule out AMI using a single blood test
• Benefits of hs-Tn 0h/1h Algorithm in ED & Hospital
• TRAPID-AMI Study: hs-TnT for Rapid Rule In/ Out of AMI
• Benefits of hs-Tn 0h/1h Algorithm to Chest Pain Patients
• Management of Cardiovascular Risks of COVID-19 Patients
• How NT-proBNP Made a Difference: Dr Januzzi’s Patient Story
• Impact of High-Sensitivity Cardiac Troponin (hs-Tn) on Further Cardiac Testing in Suspected AMI Patients
• Management of COVID-19 and the Heart, Experience from Front Line
• Advantages of Switching from Conventional to High-Sensitivity Troponin
• How hs-TnT Made a Difference – Dr Twerenbold’s Story
• How NT-proBNP Made a Difference: Dr Richards’ Patient Story
• Natriuretic Peptides in the Latest ESC & AHA HF Guidelines
• Role of Natriuretic Peptides in Patients with Dypsnea
• Novel Biomarker-based Risk Score in AF: ABC Risk Score
• Understanding Reasons for Increased Troponin Levels
• hs-TnT Rapid Diagnosis of AMI- ESC 0h/3h Algorithm
• hs-TnT Rapid Diagnosis of AMI- ESC 0h/1h Algorithm